Basic Information
ILiAD Biotechnologies, LLC (ILiAD) is a clinical-stage biotechnology company dedicated to the prevention and treatment of diseases caused by Bordetella pertussis. ILiAD's lead candidate is BPZE1, a live attenuated pertussis vaccine, which has successfully completed a Phase 1 human clinical trial.
ILiAD Biotechnologies, LLC
NewYork,NewYork,United States of America
15~50 people
January 01, 2012
info@iliadbiotech.com
Enterprise Profile
Industrial Sector
Concept
Application Scenarios